Bicara Therapeutics Inc’s filing revealed that its Officer LARA S. MEISNER acquired Company’s shares for reported $1.06 million on Mar 14 ’25. In the deal valued at $13.35 per share,79,146 shares were bought.
Then, RA CAPITAL MANAGEMENT, L.P. bought 1,833,000 shares, generating $32,994,000 in total proceeds. Upon buying the shares at $18.00, the Director now owns 4,303,418 shares.
Before that, Flynn James E bought 70,000 shares. Bicara Therapeutics Inc shares valued at $1,260,000 were divested by the Possible Members of 10% Group at a price of $18.00 per share. As a result of the transaction, Flynn James E now holds 897,587 shares, worth roughly $11.15 million.
Wedbush initiated its Bicara Therapeutics Inc [BCAX] rating to an Outperform in a research note published on February 06, 2025; the price target was $31. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering BCAX with “Buy” recommendation on November 05, 2024. TD Cowen started covering the stock on October 08, 2024. It rated BCAX as “a Buy”.
Price Performance Review of BCAX
On Friday, Bicara Therapeutics Inc [NASDAQ:BCAX] saw its stock fall -6.97% to $12.42. Over the last five days, the stock has lost -24.95%. Bicara Therapeutics Inc shares have fallen nearly -28.70% since the year began.
Levels Of Support And Resistance For BCAX Stock
The 24-hour chart illustrates a support level at 11.61, which if violated will result in even more drops to 10.79. On the upside, there is a resistance level at 13.64. A further resistance level may holdings at 14.85. The Relative Strength Index (RSI) on the 14-day chart is 42.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.83, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.67%. Stochastics %K at 23.64% indicates the stock is a holding.
How much short interest is there in Bicara Therapeutics Inc?
A steep rise in short interest was recorded in Bicara Therapeutics Inc stocks on 2025-02-28, growing by 1.53 million shares to a total of 5.61 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.08 million shares. There was a rise of 27.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $47 price target.
